<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414243</url>
  </required_header>
  <id_info>
    <org_study_id>RAF-01-015</org_study_id>
    <nct_id>NCT02414243</nct_id>
  </id_info>
  <brief_title>Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy</brief_title>
  <acronym>RAF</acronym>
  <official_title>A Multicenter, Randomized, Controlled, Cross-over Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OPBG Clinical &amp; Research Services S.R.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, controlled, multi-country study to verifying the hypoallergenicity of
      the new amino acid-based formula in infants and children aged&lt; 12 years with documented cow's
      milk protein allergy (CMPA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not Provided
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">December 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula</measure>
    <time_frame>14 days</time_frame>
    <description>To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC). Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cow's Milk Allergy Related Symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS).
The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA.
If final score &lt;12, the symptoms are less likely related to cow's milk. Look for other causes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Cow's Milk Allergy</condition>
  <arm_group>
    <arm_group_label>New Amino Acid formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Amino-Acid based Infant Formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available Amino Acid Formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>New Amino Acid formula</intervention_name>
    <description>Ordesa's Amino-Acid based Infant Formula</description>
    <arm_group_label>New Amino Acid formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Commercially available Amino Acid Formula</intervention_name>
    <description>Commercially available Amino Acid Formula</description>
    <arm_group_label>Control formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with documented cow's milk allergy, confirmed by one of the following
             criteria, within six months prior to study start (visit 2):

               -  Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's
                  milk OR

               -  Positive open or single-blind oral food challenge with cow's milk carried out
                  under the supervision of a specialist in children with clear immediate reactions
                  and a positive test for specific IgE (in serum [sIgE&gt;0,35 KUI/L] or skin prick
                  test [SPT ≥ 3 mm]) OR

               -  Reported convincing allergic symptoms following an exposure to milk or a
                  milk-containing food product and detectable serum milk-specific IgE or positive
                  skin prick test

          -  Aged ≤12 years of age at screening.

          -  Expected consumption of a minimum of 250ml of study formula per day during the open
             challenge.

          -  Written informed consent from one or both parents (depending on the local legislation)
             or legal representative.

        Exclusion Criteria:

          -  Children who receive breastfeeding at study enrolment.

          -  Had any chronic medical diseases, chromosomal or major congenital anomalies, or major
             gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency;
             antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral
             steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled
             eczema;

          -  Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast
             milk within the past 2 years;

          -  Existing illness that could interfere with formula acceptance or identification of
             allergic reactions.

          -  Investigator's uncertainty about the willingness or ability of the parents to comply
             with the protocol requirements.

          -  Participation in any other studies involving investigational or marketed products
             concomitantly or within two weeks prior to entry into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Banzato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Integrata, Verona, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Pedrosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Alonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat Bosque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Parc Taulí Sabadell, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Mª Plaza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan de Déu, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <results_first_submitted>July 25, 2019</results_first_submitted>
  <results_first_submitted_qc>January 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Amino Acid Formula + Control Formula</title>
          <description>New Amino-Acid based Infant Formula and then control formula and then open challenge with new amino acid formula
New Amino Acid formula: Ordesa's Amino-Acid based Infant Formula</description>
        </group>
        <group group_id="P2">
          <title>Control Formula + New Amino Acid Formula</title>
          <description>Commercially available Amino Acid Formula + New Amino Acid formula + open challenge with newm formula
Commercially available Amino Acid Formula: Commercially available Amino Acid Formula</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Moved to the Other Group</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Open Challenge at Home</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>41 patients randomized but 2 patients withdrew before treatment. 39 patients analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>New Aminoacid Formula + Control</title>
          <description>Patients that followed the sequence: New aminoacid formula + control formula</description>
        </group>
        <group group_id="B2">
          <title>Control Formula + New Aminoacid Formula</title>
          <description>Patients that followed the sequence: control formula + new aminoacid formula</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.43" spread="2.78"/>
                    <measurement group_id="B2" value="1.78" spread="2.27"/>
                    <measurement group_id="B3" value="2.1" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula</title>
        <description>To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC). Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study.</description>
        <time_frame>14 days</time_frame>
        <population>41 subjects were enrolled and randomized to formula sequence. Only 30 subjects completed the Open Challenge with SanorE formula.</population>
        <group_list>
          <group group_id="O1">
            <title>DBPCFC (New Milk SanorE)</title>
            <description>DBPCFC: Double blind placebo controlled food challenge (New milk)</description>
          </group>
          <group group_id="O2">
            <title>DBPCFC (Control Milk Neocate)</title>
            <description>DBPCFC: Double blind placebo controlled food challenge (control milk)</description>
          </group>
          <group group_id="O3">
            <title>Open Challenge With SanorE</title>
            <description>Open challenge with SanorE phase</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula</title>
          <description>To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC). Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study.</description>
          <population>41 subjects were enrolled and randomized to formula sequence. Only 30 subjects completed the Open Challenge with SanorE formula.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Inconclusive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cow's Milk Allergy Related Symptoms</title>
        <description>Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS).
The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA.
If final score &lt;12, the symptoms are less likely related to cow's milk. Look for other causes.</description>
        <time_frame>14 days</time_frame>
        <population>41 patients randomized but 30 completed. Results are presented as total score summary . It compares changes between visit 4 and visit 1, and comparison were performed globally. No other result available.</population>
        <group_list>
          <group group_id="O1">
            <title>Global</title>
            <description>Cow’s Milk Allergy related Symptoms (Vandenplas)</description>
          </group>
        </group_list>
        <measure>
          <title>Cow's Milk Allergy Related Symptoms</title>
          <description>Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS).
The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA.
If final score &lt;12, the symptoms are less likely related to cow's milk. Look for other causes.</description>
          <population>41 patients randomized but 30 completed. Results are presented as total score summary . It compares changes between visit 4 and visit 1, and comparison were performed globally. No other result available.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V1 Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V4 week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening visit to week 2</time_frame>
      <desc>In this study, patients received the two treatments, with the sequence A: New aminoacid formula + control formula; or sequence B: control formula + new aminoacid formula. As all patients received the two treatments, adverse events table does not difference between groups and shows global study population.
There were no serious or non-serious adverse events related to the study treatment reported in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Global</title>
          <description>Data from all participants in the study. Data has been presented globally in the final report, no results from different groups. Only occurrence of adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roser De Castellar</name_or_title>
      <organization>Laboratorios Ordesa</organization>
      <phone>+34 902105243</phone>
      <email>Roser.DeCastellar@ordesa.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

